2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-19303
    CRA-2059 256649-36-2 98%
    CRA-2059 is a highly specific and selective tryptase inhibitor, with a Ki of 620 pM for recombinant human tryptase-β (rHTβ).
    CRA-2059
  • HY-19440
    Esonarimod 101973-77-7 99.85%
    Esonarimod (KE-298) is an antirheumatic agent.
    Esonarimod
  • HY-19443
    UCB-35440 299460-62-1 99.38%
    UCB-35440 is an orally active histamine H1 receptor antagonist and 5-lipoxygenase inhibitor. UCB-35440 can be used for the research of dermatologic inflammatory conditions.
    UCB-35440
  • HY-19468
    ERB-196 550997-55-2 99.89%
    ERB-196 is a nonsteroidal selective estrogen receptor-β (ERβ) agonist.
    ERB-196
  • HY-19499
    AMG-009 1027847-67-1 98.08%
    AMG-009 is a potent antagonist of prostaglandin D2, with IC50 of 3 nM and 12 nM for CRTH2 and DP receptors, respectively.
    AMG-009
  • HY-19622
    PF-9184 1221971-47-6 98.10%
    PF-9184 is a potent and highly selective inhibitor of human microsomal prostaglandin E synthase-1 (mPGES-1), with an IC50 of 16.5 nM. PF-9184 inhibits IL-1β-induced PGE2 synthesis in vitro.
    PF-9184
  • HY-19672
    Lirimilast 329306-27-6 ≥98.0%
    Lirimilast (BAY 19-8004) is a potent, selective and orally active phosphodiesterase-4 (PDE4) inhibitor with an IC50 value of 49 nM. Lirimilast can be used for the treatment of asthma or chronic obstructive pulmonary disease (COPD). Lirimilast has potently anti-inflammatory properties.
    Lirimilast
  • HY-19675
    Naproxen etemesil 385800-16-8 99.89%
    Naproxen etemesil is a lipophilic, non-acidic, inactive proagent of naproxen that is hydrolysed to pharmacologically active Naproxen once absorbed. Naproxen is a COX-1 and COX-2 inhibitor with IC50s of 8.72 and 5.15 μM, respectively in cell assay.
    Naproxen etemesil
  • HY-19864
    Aganepag 910562-18-4 99.71%
    Aganepag is a potent Prostanoid EP2 receptor agonist, with an EC50 of 0.19 nM, and shows no activity at EP4 receptor. Aganepag can be used in the research of wound healing, scar reduction, scar prevention and wrinkle treatment and prevention.
    Aganepag
  • HY-23499
    Indeno[1,2,3-cd]pyrene 193-39-5 99.66%
    Indeno[1,2,3-cd]pyrene is a polycyclic aromatic hydrocarbon with moderate cytotoxicity in human pulmonary alveolar epithelial cells HPAEpiC. Indeno[1,2,3-cd]pyrene enhances allergic lung infammation via aryl hydrocarbon receptor.
    Indeno[1,2,3-cd]pyrene
  • HY-32346
    Atocalcitol 302904-82-1 98%
    Atocalcitol, a vitamin D3 analogue, is used in the study for psoriasis.
    Atocalcitol
  • HY-34386
    6(5H)-Phenanthridinone 1015-89-0 ≥98.0%
    6(5H)-Phenanthridinone is a potent PARP-1 inhibitor and immunomodulator. 6(5H)-Phenanthridinone inhibits cell proliferation and can be used in cancer research.
    6(5H)-Phenanthridinone
  • HY-40421
    (R)-3-Fluoropyrrolidine hydrochloride 136725-55-8 ≥98.0%
    (R)-3-Fluoropyrrolidine hydrochloride is an intermediate. (R)-3-Fluoropyrrolidine hydrochloride can be used in the synthesis of hVanin-1 inhibitor (Compound X20). (R)-3-Fluoropyrrolidine hydrochloride can be used in the research of inflammatory bowel disease.
    (R)-3-Fluoropyrrolidine hydrochloride
  • HY-44062
    G9a-IN-1 1350752-07-6 98.12%
    G9a-IN-1 (Compound 113) is a G9a protein inhibitor. G9A/EHMT2 is a nuclear histone lysine methyltransferase that catalyzes histone H3 lysine 9 dimethylation (H3K9me2), which is a reversible modification generally associated with transcriptional gene silencing. G9a-IN-1 can be used for the research of autoimmune disorders or cancer.
    G9a-IN-1
  • HY-47228
    KB-5492 free base 113594-64-2 99.02%
    KB-5492 free base is a potent and selective inhibitor of sigma receptor, inhibits specific [3H]1,3-di(2-tolyl)guanidine (DTG) binding to the sigma receptor with an IC50 of 3.15 μM. KB-5492 free base is an anti-ulcer agent.
    KB-5492 free base
  • HY-66004
    4-Acetamidophenyl acetate 2623-33-8
    4-Acetamidophenyl acetate is an impurity of Acetaminophen (HY-66005). 4-Acetamidophenyl acetate acts as an intermediate in the synthesis of Acetaminophen. Acetaminophen is a selective COX-2 inhibitor (IC50=25.8 μM), and is a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor.
    4-Acetamidophenyl acetate
  • HY-A0203
    Pentosan Polysulfate 37300-21-3 98%
    Pentosan Polysulfate is an orally bioavailable medication with anti-inflammatory and pro-chondrogenic properties. Pentosan Polysulfate also displays a potent and selective anti-HIV activity. Pentosan Polysulfatecan be used for the research of interstitial cystitis.
    Pentosan Polysulfate
  • HY-A0252
    Bupranolol 14556-46-8 98.90%
    Bupranolol is an orally active, competitive and non-selective β-adrenoceptor antagonist without intrinsic sympathomimetic activity.
    Bupranolol
  • HY-B0197
    Naratriptan 121679-13-8 99.81%
    Naratriptan is an orally active and selective 5-HT1B/1D receptor agonist. Naratriptan is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC50=0.11 μM for dog basilar artery). Naratriptan also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms.
    Naratriptan
  • HY-B0292
    Atracurium 64228-79-1 98%
    tracurium (BW-33A free acid) is a potent, competitive and non-depolarizing neuromuscular blocking agent.Atracurium also is an AChR receptor antagonist. Atracurium induces bronchoconstriction and neuromuscular blockade. Atracurium promotes astroglial differentiation.
    Atracurium
Cat. No. Product Name / Synonyms Application Reactivity